DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
BMO's Evan Seigerman Evan Seigerman - 3 Evan Seigerman - 2 BMO's Evan Seigerman - 1 Evan David Seigerman - 1 renegotiation - 1
Top related locs:
Top related orgs:
Pfizer - 3 BMO - 3 BMO Capital Markets - 2 BMO Biotech Analyst - 1 Novo Nordisk's - 1

Search resuls for: "BMO's Evan Seigerman"


6 mentions found


☆ Pfizer needs to 'fix what they have', no M&A capacity, says BMO's Evan Seigerman on activist stake
  + stars: | 2024-10-07 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailPfizer needs to 'fix what they have', no M&A capacity, says BMO's Evan Seigerman on activist stakeEvan David Seigerman, BMO Biotech Analyst, joins 'Closing Bell Overtime' to talk Pfizer shares climbing on activist firm Starboard taking a stake in the company.
Persons: BMO's Evan Seigerman, Evan David Seigerman Organizations: Pfizer, BMO Biotech Analyst
☆ GLP-1 demand is going to remain higher than supply for foreseeable future, says BMO's Evan Seigerman
  + stars: | 2024-09-24 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailGLP-1 demand is going to remain higher than supply for foreseeable future, says BMO's Evan SeigermanEvan Seigerman, BMO senior analyst, joins 'Closing Bell Overtime' to talk today's Capitol Hill hearing with Novo Nordisk's CEO and the demand for weight-loss drugs.
Persons: BMO's Evan Seigerman Evan Seigerman Organizations: BMO, Novo Nordisk's
☆ More transparency in pharmaceuticals will be a tailwind for the space, says BMO's Evan Seigerman
  + stars: | 2024-02-27 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailMore transparency in pharmaceuticals will be a tailwind for the space, says BMO's Evan SeigermanEvan Seigerman, BMO biotech analyst, joins 'Power Lunch' to discuss the health care ecosystems in pharmaceuticals.
Persons: BMO's Evan Seigerman Evan Seigerman Organizations: BMO
☆ Paxlovid contract renegotiation pushed Covid business over the edge, says BMO's Evan Seigerman
  + stars: | 2023-10-16 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailPaxlovid contract renegotiation pushed Covid business over the edge, says BMO's Evan SeigermanEvan Seigerman, BMO Capital Markets analyst, joins 'Closing Bell: Overtime' to discuss Pfizer and BioNTech cutting guidance amid Covid sales falling, the weight loss boom, and more.
Persons: renegotiation, BMO's Evan Seigerman Evan Seigerman Organizations: BMO Capital Markets, Pfizer
☆ BMO's Evan Seigerman discusses unintended consequences from Medicare drug cost battle
  + stars: | 2023-08-29 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailBMO's Evan Seigerman discusses unintended consequences from Medicare drug cost battleEvan Seigerman, biopharma sector analyst at BMO Capital Markets, joins 'The Exchange' to discuss the margin hit pharmaceutical companies will experience from Medicare drug price regulations, a reprioritization of what drugs are developed, and the time horizons for developing small molecule treatments compared to biologics.
Persons: Evan Seigerman Organizations: BMO Capital Markets
☆ BMO's Evan Seigerman says Pfizer's dip is a setback and not catastrophic
  + stars: | 2023-06-26 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailBMO's Evan Seigerman says Pfizer's dip is a setback and not catastrophicEvan Seigerman, BMO, joins 'Closing Bell' to discuss Pfizer ending its development of an experimental obesity drug.
Persons: Evan Seigerman Organizations: BMO, Pfizer
0 next >>
Total: 6